The NanoAccelTM Gas Cluster Ion Beam (GCIB) technology was originally developed to provide nanoscale surface processing of semiconductors and other opto-electronic devices. Exogenesis acquired the exclusive worldwide rights to GCIB intellectual property for biomedical applications and has subsequently developed a complementary particle beam processing technology called NanoAccel Accelerated Neutral Atom Beam (ANAB).
NASHUA, N.H.--(BUSINESS WIRE)--Vallum Corporation, a medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a polyetheretherketone (PEEK) spinal interbody fusion device with a PEEKplus® nanotextured1 surface created by Vallum’s proprietary and patented Accelerated Neutral Atom Beam (ANAB) technology.
BILLERICA, Mass., July 24, 2019 /PRNewswire/ -- Exogenesis Corporation announced today that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its first proprietary soft tissue repair device, Exogenesis Hernia Mesh. Exogenesis expects feedback from the FDA during the next quarter and anticipates entering the US market with Exogenesis Hernia Mesh following FDA premarket clearance.
BILLERICA, Mass., April 22, 2020 /PRNewswire/ -- Exogenesis announces today, the formation of nanoMesh LLC, a medical device company focused on commercialization of the Exogenesis Hernia Mesh ("nanoMesh"), an innovative soft tissue repair implant. nanoMesh possesses a unique nanometer-level surface texture, enabling favorable post implant tissue compatibility via the application of Accelerated Neutral Atom Beam (ANAB) technology during manufacturing.